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Abstract 
Background: The mechanisms leading to the high on-treatment platelet reactivity in diabetes patients are not 
fully elucidated. The genetic factors may be associated with the diminished antiplatelet efficacy of dual antiplatelet 
therapy. We investigated the possible association between insulin receptor substrate-1 (IRS-1) polymorphisms and 
high platelet reactivity in coronary artery disease (CAD) patients with type 2 diabetes mellitus (T2DM).
Methods: A total of 674 CAD patients with T2DM were enrolled in this study. Platelet aggregation and platelet activa-
tion were assessed with light transmission aggregometry and flow cytometry analysis, respectively. Participants were 
divided into high platelet reactivity (HPR) group and non-HPR group according to their maximal platelet aggregation. 
Genotypes were identified by polymerase chain reaction and direct sequencing of genomic DNA. The association 
between IRS-1 genetic variants and platelet function was assessed.
Results: There were 233 participants in the HPR group and 441 participants in the non-HPR group. G allele frequen-
cies of rs13431554 were 27.7 % for the HPR group and 18.6 % for the non-HPR group (p < 0.001). Adenosine diphos-
phate and arachidonic acid induced platelet aggregation were significantly higher in G allele carriers compared with 
non-carriers (56.8 ± 16.2 vs 52.0 ± 17.9 %, p < 0.01, 28.9 ± 18.6 vs 25.2 ± 17.8 %, p < 0.01, respectively). We observed 
that P-selectin expression and PAC-1 binding were higher in G allele carriers compared with non-carriers (40.8 ± 12.4 
vs 36.2 ± 13.8, p = 0.01; 43.7 ± 15.9 vs 38.7 ± 19.9, p = 0.03, respectively).
Conclusion: The G allele of rs13431554 in the IRS-1 gene was associated with a hyperreactive platelet phenotype in 
the CAD patients with T2DM.
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Background
Dual-antiplatelet therapy with aspirin and clopidogrel is 
the cornerstone of treatment for patients with cardiovas-
cular disease [1]. Low response to antiplatelet therapy, 
characterized as high platelet reactivity (HPR), has been 
recognized as correlating with adverse events after acute 
coronary syndromes and percutaneous coronary inter-
vention [2, 3]. The increased prevalence of low platelet 
inhibition following clopidogrel treatment and twofold 
to fourfold increased risk of cardiovascular disease were 
found in diabetes mellitus (DM) patients compared with 
non-DM patients [4–9]. Furthermore, platelet dysfunc-
tion in DM patients contributes to stent thrombosis 
and adverse events following percutaneous coronary 
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intervention [10]. The mechanisms leading to the HPR of 
DM patients are not fully elucidated. Marin F, et al. dem-
onstrated that single nucleotide polymorphisms (SNPs) 
were able to explain the variability in antiplatelet agents 
inefficacy [11]. Whether this may explain the heterogene-
ity of dual-antiplatelet therapy response in type 2 diabe-
tes mellitus (T2DM) patients remains unexplored.
Several factors including up-regulation of platelet-sign-
aling pathways have been involved in this interindividual 
response heterogeneity. Insulin inhibits platelet reactiv-
ity in the healthy individuals but not T2DM patients [4, 
12]. T2DM patients have a loss of responsiveness to insu-
lin that leads to increased platelet reactivity and reduced 
response to antiplatelet agents [11]. The loss of insulin 
signaling to Ca2+ regulating mechanisms in DM plate-
lets was accompanied by abnormal signaling initiated by 
insulin receptor substrate-1 (IRS-1). IRS-1, as a ligand 
of insulin receptor tyrosine kinase, is central to the insu-
lin signal transduction pathway [13]. Studies by Ferreira 
et al. suggested that insulin may cause platelet inhibition 
by activating IRS-1, which initiates the association with 
the Giα subunit coupled to the P2Y12 receptor [4]. Angio-
lillo et al. reported that the C allele of rs956115 in IRS-1 
was associated with a hyperreactive platelet phenotype 
in Caucasian T2DM patients [14]. However, the associa-
tions are not reproduced across other ethnic populations. 
Whether there is other SNP in IRS-1 related to HPR 
in coronary artery disease (CAD) and T2DM patients 
remains to be elucidated.
The aim of this study was to investigate the relation-
ship between the IRS-1 polymorphism and hyperreactive 
platelet phenotype in CAD patients with T2DM.
Methods
Study population
Patients with T2DM were eligible for the study if they 
were between 18 and 75  years, had undergone percuta-
neous coronary interventions (PCI), and been receiving 
standard dual antiplatelet therapy with aspirin (100 mg/
day) and clopidogrel (75  mg/day) for at least 30  days. 
Patients treated with insulin and/or oral hypoglycemic 
medications for at least 1  month were enrolled. T2DM 
was defined according to the World Health Organiza-
tion Report [15]. Exclusion criteria were as follows: a 
history of myocardial infarction fewer than 6  months 
prior to enrollment in the study; allergy/intolerance to 
aspirin or clopidogrel; impaired glucose tolerance or 
T2DM without pharmacological treatment, gestational 
diabetes, or transient hyperglycemia; use of oral antico-
agulants, and antiplatelet agents other than aspirin and 
clopidogrel; recent treatment with a glycoprotein IIb/IIIa 
antagonist; using of proton pump inhibitors; end-stage 
renal or hepatic disease; treatment with fibrin-specific 
fibrinolytic therapy <24 h or non-fibrin-specific fibrino-
lytic therapy  <48  h prior to randomization; presence of 
active internal bleeding or history of ischemic or hemor-
rhagic stroke in 6 months; platelet count <100 ×  109/L; 
hematocrit  <25  %; creatinine levels  >2.5  mg/dl; hepatic 
disease (hepatic enzymes twice the upper normal limit) 
Furthermore, to determine whether or not the findings 
were specific to patients with DM, a pharmacodynam-
ics assessment was also extended to a cohort of CAD 
patients without DM. They also received standard dual 
antiplatelet therapy with aspirin and clopidogrel for at 
least 1 month after elective PCI with the stent implanta-
tion (Additional file 1: Figure S1).
This study confirmed to the ethical guidelines of the 
Helsinki declaration. The ethics approvals were obtained 
from Shenyang Northern Hospital ethics committee and 
all patients gave their informed written consents.
Genotyping and haplotype analyses
Genomic DNA samples were extracted from peripheral 
blood lymphocytes of patients using TIANamp Blood 
DNA kits (Tiangen Biotech CO., LTD. Beijing, China). 
DNA concentration and quality were assessed using 
absorbance spectrophotometry and agarose gel electro-
phoresis, respectively. The selection of IRS-1 tag SNP was 
performed with GEVALT 2.0 software (GEnotype Visual-
ization and Algorithmic Tool) [16, 17]. The SNP genotype 
data for China (CHB) population were downloaded from 
HapMap Project Browser, submitting a 100-kilobase pair 
region as a query, with a minor allele frequency cutoff of 
0.05 and linkage disequilibrium (LD) measure r2 thresh-
old of 0.8. LD blocks were determined according to the 
gerbil algorithm [16]. Haplotype frequency was deter-
mined by means of the algorithms implemented in the 
GEVALT software, using 0.05 as the frequency thresh-
old to define common haplotypes. The specific primers 
were designed by primer 5.0 software (see Additional 
file 1: Table S1). Genotypes were identified by polymerase 
chain reaction (PCR) and direct sequencing of genomic 
DNA.
Platelet function analysis
Platelet function analysis included assessments of platelet 
aggregation and platelet activation. Platelet aggregation 
was performed with light transmission aggregometry 
according to standard protocols [18–20]. Maximal plate-
let aggregation (MPA) was assessed with platelet-rich 
plasma (PRP) by the turbidimetric method using a four-
channel Platelet Aggregation Chromogenic Kinetic 
System (Helena Laboratories,USA) after stimulus with 
adenosine diphosphate (ADP) or arachidonic acid (AA). 
PRP was prepared by centrifugation at 200g for 10 min. 
After adjustment from baseline, 20  μmol/L ADP or 
Page 3 of 8Zhang et al. Cardiovasc Diabetol  (2016) 15:50 
1 mmol/L AA was added, and aggregation was recorded 
for 10  min. Results were expressed as a percentage of 
maximal light transmission from platelet-poor plasma 
obtained from the same patient. The cutoff value of HPR 
was defined as the upper quartile of MPA.
Platelet activation was determined by assessing platelet 
surface expression of activated glycoprotein (GP) IIb/IIIa 
and P-selectin as previously described [21]. A four-color 
flow cytometry (FACSCalibur, Becton–Dickinson BD, 
USA) was used for the assessment. 50 μl whole blood was 
stimulated in  vitro with 5  μmol/L ADP before staining. 
The GPIIb/IIIa activation and P-selectin expression were 
assessed using fluorescein isothiocyanate-conjugated 
PAC-1 (PAC1-FITC) and phycoerythrin-conjugated 
anti-CD62P (CD62P-PE, Becton–Dickinson BD, USA). 
Whole blood was stained with an antibody mixture con-
taining PAC1-FITC, CD62P-PE and PerCP peridinin 
chlorophyll protein-conjugated anti-CD61 (CD61-PerCP, 
Becton–Dickinson BD, USA) monoclonal antibodies and 
incubated for 20  min in the dark at room temperature. 
After incubation, 300  μL of 0.5  % PBS-buffered para-
formaldehyde was added for fixation. Samples were ana-
lyzed within 2  h by flow cytometry. Platelet activation 
was expressed as the percentage of platelets positive for 
antibody binding.
Statistical analysis
Continuous variables were presented as mean ±  stand-
ard deviation. Categorical variables were presented 
as frequencies and percentages. They were used that 
Student’s t test for normally distributed variables and 
Mann–Whitney U test for non-normally distributed vari-
ables. χ2 test or Fisher exact test was used for categorical 
variables, as appropriate. Differences in allele and geno-
type frequencies between groups were analyzed using the 
χ2 test. P values were corrected for multiple comparisons 
for eight SNPs using the Bonferroni adjustment method, 
which changed the required significance level from <0.05 
to <0.00625 (0.05 divided by eight). The χ2 test was used 
to determine whether individual polymorphisms were at 
Hardy–Weinberg equilibrium. Results with a two-tailed 
p value < 0.05 was considered statistically significant. 
Linkage disequilibrium (LD) analysis between each pair 
of SNP was assessed using GEVALT 2.0 software. The 
power of the sample size was calculated using QUANTO 
1.2.4 software. Statistical analysis was performed using 
SPSS version 19.0 software.
Results
Baseline characteristics and platelet reactivity
Genotyping and platelet function analysis were per-
formed in a total of 674 patients. Adenosine diphosphate 
(ADP)—induced maximum platelet aggregation was 
53.8 ± 17.4 % for the 674 patients. The fourth quartile of 
maximum platelet aggregation was 65.8–86.5 %. HPR was 
defined as the 75th percentile of ADP-induced platelet 
aggregation (ADP-induced platelet aggregation >65.8 %). 
There were 233 patients with HPR and 441 patients with-
out HPR. Baseline demographics, clinical characteristics, 
and laboratory data of the study populations were listed 
in Table 1. There were no significant differences between 
the HPR and non-HPR groups for all variables. In the 
DM population, AA-induced platelet aggregation was 
44.3 ±  22.1 vs 22.9 ±  13.6 % in the HPR and non-HPR 
groups, respectively (p < 0.0001).
Genotyping distribution of IRS1
We identified eight tag SNPs including one in the exon 
(rs1801278), one in the 3′ untranslated regions (3′ UTR) 
(rs13431554), three in the introns (rs2288586, rs1078533, 
10205923) and three in the upstream and downstream 
regions(rs956115, rs1896832, rs2251692) of the IRS-1 
gene. Information of the selected tagSNP was shown in 
Additional file  1: Table S2. Genotype distributions were 
Table 1 Baseline demographic data and clinical character-
istics of the study population
Data are expressed as mean ± SD, or n (%)
BMI body mass index; LDL-C low density lipoprotein cholesterol; HDL-C high 
density lipoprotein cholesterol; HbA1C hemoglobin A1C; MI myocardial 
infarction; ACEI angiotensin converting enzyme inhibitors; ARB angiotensin II 
receptor blockers
Variable HPR (n = 233) Non-HPR (n = 441) p
Age, y 61.7 ± 9.3 62.0 ± 9.1 0.65
Males, n (%) 141 (60.5) 287 (65.1) 0.27
Smoking, n (%) 104 (44.6) 204 (46.3) 0.69
Hypertension, n (%) 169 (72.5) 292 (66.2) 0.09
BMI (kg/m2) 26.1 ± 3.4 25.9 ± 4.0 0.62
Triglycerides (mmol/L) 2.4 ± 1.8 2.3 ± 1.8 0.23
Total cholesterol (mmol/L) 4.2 ± 1.3 4.1 ± 1.1 0.12
LDL-C (mmol/L) 2.3 ± 0.9 2.2 ± 0.8 0.53
HDL-C (mmol/L) 1.1 ± 0.4 1.2 ± 0.4 0.85
HbA1C (%) 7.3 ± 1.1 7.4 ± 1.3 0.59
Hyperlipidemia, n (%) 127 (54.5) 223 (50.6) 0.33
Insulin-treated diabetes,  
n (%)
61 (26.2) 97 (22.0) 0.22
Previous MI, n (%) 48 (20.6) 102 (23.1) 0.45
Previous stroke, n (%) 27 (11.6) 36 (8.2) 0.15
Chronic renal dysfunction, 
n (%)
23 (9.9) 52 (11.8) 0.52
Essential medicine, n (%)
 ACEI/ARB 152 (62.5) 255 (57.8) 0.06
 β-blocker 139 (59.7) 275 (62.4) 0.50
 Calcium channel blocker 57 (24.5) 123 (27.9) 0.34
 Statins 211 (90.6) 394 (89.3) 0.62
 Nitrates 110 (47.2) 193 (43.8) 0.39
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all in Hardy–Weinberg equilibrium. The genotype and 
allele frequencies of the eight SNPs between the HPR 
and non-HPR groups were summarized in Table 2. Geno-
type distribution of rs13431554 was significantly differ-
ent between the HPR and non-HPR groups (p < 0.001), 
which remained statistically significant after apply-
ing Bonferroni correction. The frequencies of AA, AG, 
and GG genotypes of rs13431554 in the HPR and non-
HPR groups were 54.1, 36.5, 9.4, and 65.5, 31.7, 2.7  %, 
respectively. The G allele frequency of rs13431554 was 
significantly higher in the HPR group compared with 
the non-HPR group (27.7 vs 18.6  %, p  <  0.001, odd 
ratio  =  1.49, 95  % confidence interval  =  1.22–1.82). 
There were no significant differences in allele frequencies 
Table 2 Genotypes and allele frequencies of IRS-1 polymorphisms in primary participants
SNPs Genotype/allele HPR (n = 233) Non-HPR (n = 441) p OR (95 % CI)
rs2251692 AA, no. (%) 100 (42.9) 193 (43.8) 0.24
AG, no. (%) 114 (48.9) 195 (44.2)
GG, no. (%) 19 (8.2) 53 (12.0)
A allele 314 (67.4) 581 (65.9) 0.58 0.96 (0.82–1.12)
G allele 152 (32.6) 301 (34.1)
rs13431554 AA, no. (%) 126 (54.1) 289 (65.5) <0.001
AG, no. (%) 85 (36.5) 140 (31.7)
GG, no. (%) 22 (9.4) 12 (2.7)
A allele 337 (72.3) 718 (81.4) <0.001 1.49 (1.22–1.82)
G allele 129 (27.7) 164 (18.6)
rs10205923 AA, no. (%) 28 (12.0) 39 (8.8) 0.24
AG, no. (%) 101 (43.2) 178 (40.4)
GG, no. (%) 105 (44.9) 224 (50.8)
A allele 157 (33.5) 256 (29.0) 0.09 1.16 (0.98–1.36)
G allele 311 (66.5) 626 (71.0)
rs1078533 AA no. (%) 5 (2.1) 9 (2.0) 0.68
AC no. (%) 40 (17.2) 88 (20.0)
CC no. (%) 188 (80.7) 344 (78.0)
A allele 50 (10.7) 106 (12.0) 0.48 0.88 (0.62–1.26)
C allele 416 (89.3) 776 (88.0)
rs2288586 CC, no. (%) 134 (57.5) 283 (64.2) 0.24
CG, no. (%) 87 (37.3) 139 (31.5)
GG, no. (%) 12 (5.2) 19 (4.3)
C allele 355 (76.2) 705 (79.9) 0.11 1.19 (0.96–1.46)
G allele 111 (23.8) 177 (20.1)
rs1801278 AA no. (%) 0 (0) 0 (0) 0.58
AG no. (%) 8 (3.4) 19 (4.3)
GG no. (%) 225 (96.6) 422 (95.7)
A allele 8 (1.7) 19 (2.2) 0.59 0.80 (0.35–1.81)
G allele 458 (98.3) 863 (97.8)
rs1896832 AA, no. (%) 165 (70.8) 284 (64.4) 0.20
AG, no. (%) 62 (26.6) 147 (33.3)
GG, no. (%) 6 (2.6) 10 (2.3)
A allele 392 (84.1) 715 (81.1) 0.16 0.84 (0.65–1.08)
T allele 74 (15.9) 167 (18.9)
rs956115 CC, no. (%) 2 (0.9) 10 (2.3) 0.28
CG, no. (%) 50 (21.5) 107 (24.3)
GG, no. (%) 181 (77.7) 324 (73.5)
C allele 54 (11.6) 137 (14.4) 0.15 1.03 (0.99–1.08)
G allele 412 (88.4) 755 (85.6)
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or genotype distributions among the remaining seven 
SNPs between the HPR and non-HPR patients.
In the cohort of CAD patients without DM, the fre-
quencies of AA, AG and GG genotypes of rs13431554 in 
the HPR and non-HPR groups were 68.8, 22.9,8.3, and 
63.6, 30.7, 5.7 % respectively, (p = 0.52). We found that 
there were no significant differences in genotype and 
allele frequencies between the HPR and non-HPR group 
in non-DM patients (Additional file 1: Table S3).
Rs13431554 polymorphism and platelet activity
Because of the low occurrence of patients with the GG 
genotype, the G allele carriers (AG + GG) were ascribed 
to a single group. Individuals who carried the G allele had 
higher platelet aggregation compared with non-carriers 
(Fig. 1a; Table 3) no matter with the ADP-or AA-induced 
platelet aggregation (56.8  ±  16.2 vs 52.0  ±  17.9  %, 
p < 0.01 for ADP; 28.9 ± 18.6 vs 25.2 ± 17.8 %, p < 0.01 
for AA).
Platelet surface expression of activated glycopro-
tein IIb/IIIa and P-selectin were assessed to confirm 
the association between platelet activation and the 
alleles of rs13431554. P-selectin expression and glyco-
protein IIb/IIIa activation on the platelet surface were 
increased in the rs13431554 G allele carriers (40.8 ± 12.4 
vs 36.2  ±  13.8  %, p  =  0.01 for PAC-1; 43.7  ±  15.9 vs 
38.7 ± 19.9 %, p = 0.03 for P-selectin) (Fig. 1b; Table 3).
In the external validation cohort of patients with-
out DM, the ADP-induced platelet aggregations were 
48.5  ±  17.4 and 51.1  ±  18.6  % (p  =  0.35), and AA-
induced platelet aggregations were 22.3  ±  14.9 and 
24.8 ±  16.4  % (p =  0.29) between G allele carriers and 
non-carriers. There was no significant difference between 
the rs13431554 G genotype and platelet activation in 
non-DM patients (34.8 ± 11.8 vs 36.5 ± 13.1 %, p = 0.37 
for PAC-1; 36.4  ±  17.0 vs 39.0  ±  16.2  %, p  =  0.31 for 
P-selectin) (Table 3).
IRS-1 haplotypes analysis
LD analysis of the eight SNPs revealed three LD blocks, 
as defined according to the gerbil algorithm (see Addi-
tional file 1: Table S4). Three haplotype LD blocks were 
identified for the IRS-1 gene region: block-1 (rs2251692-
rs13431554-rs10205923-rs1078533); block-2 (rs2288586-
rs1801278); and block-3 (rs1896832-rs956115) (Fig.  2a). 
Haplotype frequencies were shown in Fig. 2b.
We investigated the associations between haplotype 
LD block frequencies and high platelet activity. There was 
no significant association among the three blocks with 
any of the phenotypes investigated, even though haplo-
type block-1 (AGAC) frequency exactly corresponded to 
the G allele of rs13431554.
Discussion
In healthy subjects, platelets are inhibited by insulin 
leading to reduced Ca2+ mobilization and aggregate 
formation [8]. Studies have demonstrated that platelet 
hyperactivity in T2DM is likely to be caused by a defect 
in the mechanisms through which insulin interferes with 
signaling by the P2Y12 receptor. After binding with its 
receptor, insulin activates IRS-1 through tyrosine phos-
phorylation, which initiates the association with the 
Giα-subunit. Then, Giα activity is inhibited and impairs 
suppression of adenylyl cyclase through P2Y12. Patients 
with T2DM are at particularly risk for restenosis and 
repeat the revascularization procedures because of the 
increased platelet activation and the reduced platelet 
inhibition by antiplatelet agents [22–25].
Fig. 1 Platelet aggregation and platelet activation for rs13431554 genotypes. Platelet aggregation following adenosine diphosphate and arachi-
donic acid stumuli (a) and platelet activation (PAC-1 binding and P-selectin expression) following adenosine diphosphate stimuli (b) in the AA 
group compared with the AG + GG group according to rs13431554 genotype
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This study suggested that IRS-1 polymorphism has an 
effect on platelet response to dual-antiplatelet therapy in 
CAD patients with T2DM. The eight SNPs of IRS-1 gene 
were examined to study the association between the pol-
ymorphisms and the hyperreactive platelet phenotype. 
We found that the G allele of IRS-1 rs13431554 poly-
morphism was significant associated with high platelet 
activity. The variant is located in the 3′UTR region of 
IRS-1, which is more important for mRNA stability, 
localization, and translational efficiency.
It has been reported that the binding affinity between 
miRNA and its target mRNA may be changed by SNP 
located at miRNA target sites [26]. SNP variant may 
lead to the degradation of mRNA and the inhibition of 
mRNA translation into protein [27]. Based on our bio-
informatics analysis using the microRNA.org database 
[28], has-miR-23 and has-miR-130 which binding to the 
sequence surrounding the variant site were identified. 
These bioinformatics forecasts indicated that rs13431554 
may affect the binding affinity between IRS-1 mRNA and 
miRNAs, which may alter the expression of IRS-1 gene. It 
is reasonable to suggest that rs13431554 might influence 
miRNA biogenesis and function, also contribute to plate-
let activity. Further functional evaluations are needed to 
confirm this hypothesis.
The heterogeneity of antiplatelet drug efficacy is known 
to vary according to the genetic background. Cytochrome 
P450 (CYP) polymorphism correlates with the dimin-
ished antiplatelet efficacy of clopidogrel and the high 
risk for adverse cardiovascular events following stent 
implantation [29–32]. The impact of CYP2C19 polymor-
phism on platelet reactivity to clopidogrel seems to be 
more significant in non-DM patients compared with DM 
patients [33]. Precise clinical phenotypes and functional 
characterizations of gene variants are currently lacking. 
An early study reported that T2DM patients with the 
C allele of the rs956115 marker of the IRS-1 gene have 
a hyperreactive platelet phenotype and increased risk of 
major adverse cardiac events [14]. However, this result 
was not observed in our study. Possible explanation for 
these divergent results may lie in the ethnic differences 
in genetic backgrounds. The rs956115 polymorphism is 
located in the 5′region of the IRS-1 gene which doesn’t 
affect amino acid coding and protein function. The 
rs13431554 polymorphism is located in in the 3′region 
of the IRS-1 gene, and may be more important to the 
Table 3 Platelet function profiles according to rs13431554 genotype in study population
Data are expressed as mean ± SD of percentages of platelet aggregation or percentages of positive platelets
ADP adenosine diphosphate; AA arachidonic acid
DM patients p Non-DM patients p
AA AG + GG AA AG + GG
Platelet aggregation (%)
 ADP 52.0 ± 17.9 56.8 ± 16.2 <0.01 48.5 ± 17.4 51.1 ± 18.6 0.35
 AA 25.2 ± 17.8 28.9 ± 18.6 <0.01 22.3 ± 14.9 24.8 ± 16.4 0.29
Platelet activation (%)
 PAC-1 36.2 ± 13.8 40.8 ± 12.4 0.01 34.8 ± 11.8 36.5 ± 13.1 0.37
 P-selectin 38.7 ± 19.9 43.7 ± 15.9 0.03 36.4 ± 17.0 39.0 ± 16.2 0.31
Fig. 2 Linkage disequilibrium plot for SNPs in the IRS-1 gene. Linkage 
disequilibrium between markers was measured by pairwise D’ as 
calculated from the sample of individuals studied. a Linkage disequi-
librium blocks were identified as suggested by the gerbil algorithm. 
Color support for D’ estimation as reported in the computer program 
Haploview (Barrett JC et al., 2005). White D’ <1 and LOD <2; shades 
of pink/red D’ <1 and LOD ≥2; red D’ = 1 and LOD ≥2. Number in 
the square: D’ value expressed as estimated D’ value × 100; empty 
square D’ = 1. b Haplotypes with a frequency >5 % in the two linkage 
disequilibrium blocks
Page 7 of 8Zhang et al. Cardiovasc Diabetol  (2016) 15:50 
function of IRS-1. We found that the outcomes were 
special to DM patients because there was no significant 
association between IRS-1 polymorphism and platelet 
activity in non-DM cohort. We did not find the associa-
tion between the haplotype LD blocks and high platelet 
activity phenotypes in our study.
Glycemic control has an effect on platelet reactivity in 
diabetic patients. Previous study showed that a reduc-
tion in HbA1c level was associated with a reduction in 
blood thrombogenicity. Grzegorz Gajos et  al. demon-
strated that fasting glycemia <4.5 mmol/L was associated 
with enhanced thrombin formation in T2DM patients, 
especially when strict glycemic control was achieved 
(HbA1c <6.0 %) [34]. Patients in our study had got a good 
glycemic control and limited variability in HbA1C levels, 
so the level of HbA1C didn’t affect our study results.
More strategies are being studied to overcome 
increased platelet reactivity in DM patients. Previous 
study showed that using a loading dose of clopidogrel 
rather than small daily doses was not sufficient for ade-
quately overcoming increased platelet reactivity in DM 
patients, highlighting the need for more effective anti-
platelet drugs for such patients [35]. And, novel P2Y12 
receptor blockers such as prasugrel and ticagrelor were 
found that they were superiors in terms of pharmaco-
dynamics and pharmacokinetic effects than clopidogrel 
[36–38]. Recent randomized studies also demonstrated 
that ticagrelor was superior to prasugrel for reducing 
platelet reactivity in subjects with diabetes [39].
This is the first study to evaluate the association 
between IRS-1 polymorphism and high on-treatment 
platelet reactivity in a population of Chinese CAD 
patients with DM. Identification of susceptible genes 
that contribute to the declining platelet response may 
facilitate prediction, prevention, and development of 
improved antiplatelet treatments.
Study limitations
There is a lack of standardization identification of opti-
mal cutoff values for defining the HPR [40]. Standard-
ized definitions of defining individual responsiveness to 
clopidogrel should be used in further experiments. We 
assessed platelet reactivity in  vitro, that can’t fully rep-
resent platelet phenotype in circulating condition. The 
mechanisms of the rs13431554 variant contributing 
to the poor response to clopidogrel in T2DM patients 
remain speculative. Further functional evaluations with 
larger sample sizes are needed to confirm our findings. 
Different geographical and ethnic backgrounds of the 
study participants may affect the results of any asso-
ciation study. Therefore, more patients of different geo-
graphical areas and ethnicities should be included to 
confirm our conclusions in the further studies.
Conclusions
Variant rs13431554 in the IRS-1 gene is associated with 
a hyperreactive platelet phenotype and a sub-optimal 
response to antiplatelet drug in CAD patients with T2DM. 
There is an association between the G allele of rs13431554 
and the increased platelet aggregation and activity. Fur-
ther validations using larger sample sizes of diverse ethnic 
populations and functional evaluations are warranted.
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